Clinical Trials Logo

Advanced NSCLC clinical trials

View clinical trials related to Advanced NSCLC.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06356675 Not yet recruiting - Advanced NSCLC Clinical Trials

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Start date: July 1, 2024
Phase: Phase 4
Study type: Interventional

Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes.

NCT ID: NCT05859217 Not yet recruiting - Lung Cancer Clinical Trials

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Cabatezo-1
Start date: December 2024
Phase: Phase 2
Study type: Interventional

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.

NCT ID: NCT04992858 Not yet recruiting - Advanced NSCLC Clinical Trials

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Start date: November 27, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II, Single-arm,Open-label Study evaluating the safety and efficacy of CT053PTSA in Advanced Solid Tumors With MET Exon 14 Skipping Mutations

NCT ID: NCT04229121 Not yet recruiting - Clinical trials for Circulating Tumor DNA

Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients

Start date: January 15, 2020
Phase:
Study type: Observational

Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation